Literature DB >> 16733480

An assessment of downward trends in neurodevelopmental disorders in the United States following removal of Thimerosal from childhood vaccines.

David A Geier1, Mark R Geier.   

Abstract

BACKGROUND: The US is in the midst of an epidemic of neurodevelopmental disorders (NDs). Thimerosal is an ethylmercury-containing compound added to some childhood vaccines. Several previous epidemiological studies conducted in the US have associated Thimerosal-containing vaccine (TCV) administration with NDs. MATERIAL/
METHODS: An ecological study was undertaken to evaluate NDs reported to the Vaccine Adverse Event Reporting System (VAERS) from 1991 through 2004 by date of receipt and by date of vaccine administration. The NDs examined included autism, mental retardation, and speech disorders. Statistical trend analysis was employed to evaluate the effects of removal of Thimerosal on the proportion of NDs reported to VAERS.
RESULTS: There was a peak in the proportion of ND reports received by VAERS in 2001-2002 and in the proportion of ND reports by date of vaccine administration in 1998. There were significant reductions in the proportion of NDs reported to VAERS as Thimerosal was begun to be removed from childhood vaccines in the US from mid-1999 onwards.
CONCLUSIONS: The present study provides the first epidemiological evidence showing that as Thimerosal was removed from childhood vaccines, the number of NDs has decreased in the US. The analysis techniques utilized attempted to minimize chance or bias/confounding. Additional research should be conducted to further evaluate the relationship between TCVs and NDs. This is especially true because the handling of vaccine safety data from the National Immunization Program of the CDC has been called into question by the Institute of Medicine of the National Academy of Sciences in 2005.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16733480

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  6 in total

1.  The rise in autism and the role of age at diagnosis.

Authors:  Irva Hertz-Picciotto; Lora Delwiche
Journal:  Epidemiology       Date:  2009-01       Impact factor: 4.822

Review 2.  Abating Mercury Exposure in Young Children Should Include Thimerosal-Free Vaccines.

Authors:  José G Dórea
Journal:  Neurochem Res       Date:  2017-04-24       Impact factor: 3.996

3.  A Cross-Sectional Study of the Association between Infant Hepatitis B Vaccine Exposure in Boys and the Risk of Adverse Effects as Measured by Receipt of Special Education Services.

Authors:  David A Geier; Janet K Kern; Kristin G Homme; Mark R Geier
Journal:  Int J Environ Res Public Health       Date:  2018-01-12       Impact factor: 3.390

4.  A longitudinal cohort study of the relationship between Thimerosal-containing hepatitis B vaccination and specific delays in development in the United States: Assessment of attributable risk and lifetime care costs.

Authors:  David A Geier; Janet K Kern; Brian S Hooker; Paul G King; Lisa K Sykes; Mark R Geier
Journal:  J Epidemiol Glob Health       Date:  2015-07-09

5.  Premature Puberty and Thimerosal-Containing Hepatitis B Vaccination: A Case-Control Study in the Vaccine Safety Datalink.

Authors:  David A Geier; Janet K Kern; Mark R Geier
Journal:  Toxics       Date:  2018-11-15

6.  Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.

Authors:  James B Adams; Matthew Baral; Elizabeth Geis; Jessica Mitchell; Julie Ingram; Andrea Hensley; Irene Zappia; Sanford Newmark; Eva Gehn; Robert A Rubin; Ken Mitchell; Jeff Bradstreet; Jane El-Dahr
Journal:  BMC Clin Pharmacol       Date:  2009-10-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.